Stakeholder roles: Government, tech, healthcare providers and life sciences companies have the most to gain from delivering on AI’s promise to detect disease earlier. However, doing so will require these stakeholders to gather and share data, best practices and algorithms across organizations and borders while collaborating to build a baseline level of public trust. The positive public health implications of detecting diseases earlier make it a ripe opportunity for public-private partnership between governments and other entities. Connectors must continue to create awareness of and cultivate confidence in AI-driven approaches to patient risk stratification. Payers must continually evaluate and update their reimbursement policies to reflect new approaches and to incentivize the medical community to embrace them. Public-private matrix for accelerating AI-driven diagnosis and risk stratification F I GUR E 4 Note: Connectors defined as NGOs, advocacy and patient groups, distributors, group purchasing organizations, investors and other organizations in healthcare. Use case/ stakeholders Government Connectors Technology Life sciences/ medtech Providers Payers AI-driven diagnosis and risk stratification Relatively more supportive role Relatively more central role Scaling Smart Solutions with AI in Health: Unlocking Impact on High-Potential Use Cases 12
RkJQdWJsaXNoZXIy NzQwMjQ=